Novo Nordisk A/S (NYSE:NVO) Shares Purchased by Argus Investors Counsel Inc.

Argus Investors Counsel Inc. boosted its holdings in Novo Nordisk A/S (NYSE:NVO) by 15.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,579 shares of the company’s stock after purchasing an additional 475 shares during the quarter. Argus Investors Counsel Inc.’s holdings in Novo Nordisk A/S were worth $308,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. AQR Capital Management LLC increased its stake in Novo Nordisk A/S by 110.5% during the second quarter. AQR Capital Management LLC now owns 17,164 shares of the company’s stock worth $2,450,000 after acquiring an additional 9,012 shares during the last quarter. Mather Group LLC. increased its stake in Novo Nordisk A/S by 4.3% during the third quarter. Mather Group LLC. now owns 5,835 shares of the company’s stock worth $695,000 after acquiring an additional 243 shares during the last quarter. Park Place Capital Corp acquired a new stake in Novo Nordisk A/S during the third quarter worth about $119,000. Olistico Wealth LLC increased its stake in Novo Nordisk A/S by 6.3% during the third quarter. Olistico Wealth LLC now owns 7,731 shares of the company’s stock worth $921,000 after acquiring an additional 460 shares during the last quarter. Finally, Gratus Wealth Advisors LLC increased its stake in Novo Nordisk A/S by 69.0% during the third quarter. Gratus Wealth Advisors LLC now owns 3,693 shares of the company’s stock worth $435,000 after acquiring an additional 1,508 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Trading Up 3.9 %

Shares of NVO opened at $85.83 on Thursday. The company has a market capitalization of $385.16 billion, a P/E ratio of 27.78, a P/E/G ratio of 0.93 and a beta of 0.45. Novo Nordisk A/S has a one year low of $78.17 and a one year high of $148.15. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The stock has a 50-day moving average price of $92.24 and a 200 day moving average price of $112.01.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 86.32% and a net margin of 35.03%. Sell-side analysts forecast that Novo Nordisk A/S will post 3.16 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on NVO shares. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Finally, BMO Capital Markets decreased their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research report on Monday, December 23rd. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.